Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2013

Open Access 01-12-2013 | Research article

A threshold method for immunological correlates of protection

Authors: Xuan Chen, Fabrice Bailleux, Kamal Desai, Li Qin, Andrew J Dunning

Published in: BMC Medical Research Methodology | Issue 1/2013

Login to get access

Abstract

Background

Immunological correlates of protection are biological markers such as disease-specific antibodies which correlate with protection against disease and which are measurable with immunological assays. It is common in vaccine research and in setting immunization policy to rely on threshold values for the correlate where the accepted threshold differentiates between individuals who are considered to be protected against disease and those who are susceptible. Examples where thresholds are used include development of a new generation 13-valent pneumococcal conjugate vaccine which was required in clinical trials to meet accepted thresholds for the older 7-valent vaccine, and public health decision making on vaccination policy based on long-term maintenance of protective thresholds for Hepatitis A, rubella, measles, Japanese encephalitis and others. Despite widespread use of such thresholds in vaccine policy and research, few statistical approaches have been formally developed which specifically incorporate a threshold parameter in order to estimate the value of the protective threshold from data.

Methods

We propose a 3-parameter statistical model called the a:b model which incorporates parameters for a threshold and constant but different infection probabilities below and above the threshold estimated using profile likelihood or least squares methods. Evaluation of the estimated threshold can be performed by a significance test for the existence of a threshold using a modified likelihood ratio test which follows a chi-squared distribution with 3 degrees of freedom, and confidence intervals for the threshold can be obtained by bootstrapping. The model also permits assessment of relative risk of infection in patients achieving the threshold or not. Goodness-of-fit of the a:b model may be assessed using the Hosmer-Lemeshow approach. The model is applied to 15 datasets from published clinical trials on pertussis, respiratory syncytial virus and varicella.

Results

Highly significant thresholds with p-values less than 0.01 were found for 13 of the 15 datasets. Considerable variability was seen in the widths of confidence intervals. Relative risks indicated around 70% or better protection in 11 datasets and relevance of the estimated threshold to imply strong protection. Goodness-of-fit was generally acceptable.

Conclusions

The a:b model offers a formal statistical method of estimation of thresholds differentiating susceptible from protected individuals which has previously depended on putative statements based on visual inspection of data.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegrist CA, Plotkin SA, Orenstein W: The immunology of vaccintion. Vaccines. 2008, Offit PA: Elsevier, 17-36. 5 Siegrist CA, Plotkin SA, Orenstein W: The immunology of vaccintion. Vaccines. 2008, Offit PA: Elsevier, 17-36. 5
7.
go back to reference Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG: A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis. 2007, 196 (9): 1304-1312. 10.1086/522428.CrossRefPubMed Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG: A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis. 2007, 196 (9): 1304-1312. 10.1086/522428.CrossRefPubMed
8.
go back to reference Gilbert PB, Qin L, Self SG: Evaluating a surrogate endpoint at three levels, with application to vaccine development. Stat Med. 2007, 27: 4758-4778.CrossRef Gilbert PB, Qin L, Self SG: Evaluating a surrogate endpoint at three levels, with application to vaccine development. Stat Med. 2007, 27: 4758-4778.CrossRef
9.
go back to reference Plotkin SA, Gilbert PG: Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis. 2012, 54 (11): 1615-1617. 10.1093/cid/cis238.CrossRefPubMedPubMedCentral Plotkin SA, Gilbert PG: Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis. 2012, 54 (11): 1615-1617. 10.1093/cid/cis238.CrossRefPubMedPubMedCentral
12.
go back to reference Björkholm B, Böttiger M, Christenson B, Hagberg L: Antitoxin antibody levels and the outcome of illness during an outbreak of diphtheria among alcoholics. Scand J Infect Dis. 1986, 18 (3): 235-239. 10.3109/00365548609032332.CrossRefPubMed Björkholm B, Böttiger M, Christenson B, Hagberg L: Antitoxin antibody levels and the outcome of illness during an outbreak of diphtheria among alcoholics. Scand J Infect Dis. 1986, 18 (3): 235-239. 10.3109/00365548609032332.CrossRefPubMed
14.
go back to reference Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA: Measles antibody: reevaluation of protective titers. J Infect Dis. 1990, 162 (5): 1036-1042. 10.1093/infdis/162.5.1036.CrossRefPubMed Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA: Measles antibody: reevaluation of protective titers. J Infect Dis. 1990, 162 (5): 1036-1042. 10.1093/infdis/162.5.1036.CrossRefPubMed
15.
go back to reference Neumann PW, Weber JM, Jessamine AG, O’Shaughnessy MV: Comparison of measles antihemolysin test, enzyme-linked immunosorbent assay, and hemagglutination inhibition test with neutralization test for determination of immune status. J Clin Microbiol. 1985, 22 (2): 296-298.PubMedPubMedCentral Neumann PW, Weber JM, Jessamine AG, O’Shaughnessy MV: Comparison of measles antihemolysin test, enzyme-linked immunosorbent assay, and hemagglutination inhibition test with neutralization test for determination of immune status. J Clin Microbiol. 1985, 22 (2): 296-298.PubMedPubMedCentral
16.
go back to reference Goldschneider I, Gotschlich EC, Artenstein MS: Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969, 129 (6): 1327-1348.PubMed Goldschneider I, Gotschlich EC, Artenstein MS: Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969, 129 (6): 1327-1348.PubMed
17.
go back to reference White CJ, Kuter BJ, Ngai A, Hildebrand CS, Isganitis KL, Patterson CM, Capra A, Miller WJ, Krah DL, Provost PJ, Ellis RW, Calandra GB: Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J. 1992, 11: 19-23. 10.1097/00006454-199201000-00006.CrossRefPubMed White CJ, Kuter BJ, Ngai A, Hildebrand CS, Isganitis KL, Patterson CM, Capra A, Miller WJ, Krah DL, Provost PJ, Ellis RW, Calandra GB: Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J. 1992, 11: 19-23. 10.1097/00006454-199201000-00006.CrossRefPubMed
18.
go back to reference Siber GR: Methods for estimating serological correlates of protection. Dev Biol Stand. 1997, 89: 283-296.PubMed Siber GR: Methods for estimating serological correlates of protection. Dev Biol Stand. 1997, 89: 283-296.PubMed
19.
go back to reference Jódar L, Butler J, Carlone G, Dagan R, Goldblatt D, Käyhty H, Klugman K, Plikaytis B, Siber G, Kohberger R, Chang I, Cherian T: Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine. 2003, 21 (23): 3265-3272. 10.1016/S0264-410X(03)00230-5.CrossRefPubMed Jódar L, Butler J, Carlone G, Dagan R, Goldblatt D, Käyhty H, Klugman K, Plikaytis B, Siber G, Kohberger R, Chang I, Cherian T: Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine. 2003, 21 (23): 3265-3272. 10.1016/S0264-410X(03)00230-5.CrossRefPubMed
20.
go back to reference Siber GR, Chang I, Baker S, Fernsten P, O’Brien KL, Santosham M, Klugman KP, Madhi SA, Paradiso P, Kohberger R: Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007, 25: 3816-3826. 10.1016/j.vaccine.2007.01.119.CrossRefPubMed Siber GR, Chang I, Baker S, Fernsten P, O’Brien KL, Santosham M, Klugman KP, Madhi SA, Paradiso P, Kohberger R: Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007, 25: 3816-3826. 10.1016/j.vaccine.2007.01.119.CrossRefPubMed
21.
go back to reference Advisory Committee on Immunization Practices: Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children. MMWR Morb Mortal Wkly Rep. 2010, 59 (9): 258-261. Advisory Committee on Immunization Practices: Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children. MMWR Morb Mortal Wkly Rep. 2010, 59 (9): 258-261.
22.
go back to reference Andrews N, Borrow R, Miller E: Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003, 10 (5): 780-786.PubMedPubMedCentral Andrews N, Borrow R, Miller E: Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003, 10 (5): 780-786.PubMedPubMedCentral
23.
go back to reference Cherry JD, Gornbein J, Heininger U, Stehr K: A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 1998, 16 (20): 1901-1906. 10.1016/S0264-410X(98)00226-6.CrossRefPubMed Cherry JD, Gornbein J, Heininger U, Stehr K: A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 1998, 16 (20): 1901-1906. 10.1016/S0264-410X(98)00226-6.CrossRefPubMed
24.
go back to reference Dagan R, Givon-Lavi N, Fraser D, Lipsitch M, Siber GR, Kohberger R: Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis. 2005, 192 (3): 367-376. 10.1086/431679.CrossRefPubMed Dagan R, Givon-Lavi N, Fraser D, Lipsitch M, Siber GR, Kohberger R: Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis. 2005, 192 (3): 367-376. 10.1086/431679.CrossRefPubMed
25.
go back to reference Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J: A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med. 1996, 334 (6): 349-355. 10.1056/NEJM199602083340602.CrossRefPubMed Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J: A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med. 1996, 334 (6): 349-355. 10.1056/NEJM199602083340602.CrossRefPubMed
26.
go back to reference Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP: Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine. 2003, 21 (24): 3479-3482. 10.1016/S0264-410X(03)00355-4.CrossRefPubMed Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP: Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine. 2003, 21 (24): 3479-3482. 10.1016/S0264-410X(03)00355-4.CrossRefPubMed
27.
go back to reference Stehr K, Cherry JD, Heininger U, Schmitt-Grohé S, Überall M, Laussucq S, Eckhardt T, Meyer M, Engelhardt R, Christenson P, the Pertussis Vaccine Study Group: A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics. 1998, 101 (1): 1-11. 10.1542/peds.101.1.1.CrossRefPubMed Stehr K, Cherry JD, Heininger U, Schmitt-Grohé S, Überall M, Laussucq S, Eckhardt T, Meyer M, Engelhardt R, Christenson P, the Pertussis Vaccine Study Group: A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics. 1998, 101 (1): 1-11. 10.1542/peds.101.1.1.CrossRefPubMed
28.
go back to reference Storsaeter J, Hallander HO, Gustafsson L, Olin P: Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 1998, 16: 1907-1916. 10.1016/S0264-410X(98)00227-8.CrossRefPubMed Storsaeter J, Hallander HO, Gustafsson L, Olin P: Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 1998, 16: 1907-1916. 10.1016/S0264-410X(98)00227-8.CrossRefPubMed
29.
go back to reference Rapola S, Jantti V, Eerola M, Makela PH, Kayhty H, Kilpi T: Anti-PsaA and the risk of pneumococcal AOM and carriage. Vaccine. 2003, 21: 3608-3613. 10.1016/S0264-410X(03)00409-2.CrossRefPubMed Rapola S, Jantti V, Eerola M, Makela PH, Kayhty H, Kilpi T: Anti-PsaA and the risk of pneumococcal AOM and carriage. Vaccine. 2003, 21: 3608-3613. 10.1016/S0264-410X(03)00409-2.CrossRefPubMed
30.
go back to reference Jokinen JT, Ahman H, Kilpi TM, Mäkelä PH, Käyhty H: Concentration of antipneumococcal antibodies as a serological correlate of protection: An application to acute otitis media. J Infect Dis. 2004, 190: 545-550. 10.1086/422531.CrossRefPubMed Jokinen JT, Ahman H, Kilpi TM, Mäkelä PH, Käyhty H: Concentration of antipneumococcal antibodies as a serological correlate of protection: An application to acute otitis media. J Infect Dis. 2004, 190: 545-550. 10.1086/422531.CrossRefPubMed
31.
go back to reference Chan I, Li S, Matthews H, Chan C, Vessey R, Sadoff J, Heyse J: Use of statistical models for evaluating antibody response as a correlate of protection against varicella. Stat Med. 2002, 21 (22): 3411-3430. 10.1002/sim.1268.CrossRefPubMed Chan I, Li S, Matthews H, Chan C, Vessey R, Sadoff J, Heyse J: Use of statistical models for evaluating antibody response as a correlate of protection against varicella. Stat Med. 2002, 21 (22): 3411-3430. 10.1002/sim.1268.CrossRefPubMed
32.
go back to reference Dunning AJ: A model for immunological correlates of protection. Stat Med. 2006, 25: 1485-1497. 10.1002/sim.2282.CrossRefPubMed Dunning AJ: A model for immunological correlates of protection. Stat Med. 2006, 25: 1485-1497. 10.1002/sim.2282.CrossRefPubMed
33.
go back to reference Coudeville L, Bailleux F, Riche B, Megas F, André P, Ecochard R: Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol. 2010, 10 (1): 18-10.1186/1471-2288-10-18.CrossRefPubMedPubMedCentral Coudeville L, Bailleux F, Riche B, Megas F, André P, Ecochard R: Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol. 2010, 10 (1): 18-10.1186/1471-2288-10-18.CrossRefPubMedPubMedCentral
34.
go back to reference Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, Tam JS, Rappaport R, Eldridge JH, Gruber WC: Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol. 2008, 15 (7): 1042-1053. 10.1128/CVI.00397-07.CrossRefPubMedPubMedCentral Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, Tam JS, Rappaport R, Eldridge JH, Gruber WC: Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol. 2008, 15 (7): 1042-1053. 10.1128/CVI.00397-07.CrossRefPubMedPubMedCentral
35.
go back to reference Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R: Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011, 30 (12): 1081-1085. 10.1097/INF.0b013e3182367662.CrossRefPubMed Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R: Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011, 30 (12): 1081-1085. 10.1097/INF.0b013e3182367662.CrossRefPubMed
36.
go back to reference Miller R, Siegmund D: Maximally selected chi square statistics. Biometrics. 1982, 38: 1011-1016. 10.2307/2529881.CrossRef Miller R, Siegmund D: Maximally selected chi square statistics. Biometrics. 1982, 38: 1011-1016. 10.2307/2529881.CrossRef
37.
go back to reference Efron B, Tibshirani R: An Introduction to the Bootstrap. Boca Raton. 1994, : Chapman & Hall/CRC Press LLC Efron B, Tibshirani R: An Introduction to the Bootstrap. Boca Raton. 1994, : Chapman & Hall/CRC Press LLC
38.
go back to reference Hosmer DW, Lemeshow S, Klar J: Goodness-of-fit testing for the multiple logistic regression when the estimated probabilities are small. Biom J. 1988, 30: 911-924. 10.1002/bimj.4710300805.CrossRef Hosmer DW, Lemeshow S, Klar J: Goodness-of-fit testing for the multiple logistic regression when the estimated probabilities are small. Biom J. 1988, 30: 911-924. 10.1002/bimj.4710300805.CrossRef
39.
go back to reference Gershon AA, Takahashi M, Seward J: Varicella Vaccine. Vaccines. Edited by: Plotkin SA, Orenstein W. 2008, Offit PA: Elsevier, 915-958. 5 Gershon AA, Takahashi M, Seward J: Varicella Vaccine. Vaccines. Edited by: Plotkin SA, Orenstein W. 2008, Offit PA: Elsevier, 915-958. 5
41.
42.
go back to reference Wolfson J, Peter Gilbert PB: Statistical identifiability and the surrogate endpoint problem. Biometrics. 2010, 66: 1153-1161. 10.1111/j.1541-0420.2009.01380.x.CrossRefPubMedPubMedCentral Wolfson J, Peter Gilbert PB: Statistical identifiability and the surrogate endpoint problem. Biometrics. 2010, 66: 1153-1161. 10.1111/j.1541-0420.2009.01380.x.CrossRefPubMedPubMedCentral
43.
go back to reference Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000, 19 (3): 187-195. 10.1097/00006454-200003000-00003.CrossRefPubMed Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000, 19 (3): 187-195. 10.1097/00006454-200003000-00003.CrossRefPubMed
44.
go back to reference Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S: Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis. 2010, 51 (9): 997-1004. 10.1086/656578.CrossRefPubMed Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S: Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis. 2010, 51 (9): 997-1004. 10.1086/656578.CrossRefPubMed
45.
go back to reference Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR: Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006, 354 (1): 11-22. 10.1056/NEJMoa052434.CrossRefPubMed Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR: Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006, 354 (1): 11-22. 10.1056/NEJMoa052434.CrossRefPubMed
Metadata
Title
A threshold method for immunological correlates of protection
Authors
Xuan Chen
Fabrice Bailleux
Kamal Desai
Li Qin
Andrew J Dunning
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2013
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/1471-2288-13-29

Other articles of this Issue 1/2013

BMC Medical Research Methodology 1/2013 Go to the issue